Novavax, Inc. Financials

Market Capitalization $1.10 Billion as of July 1, 2025

Valuations Metrics as of Jul. 5, 2025

Trailing PE	2.47
Forward PE	-42.50
Price to Sales TTM	$0.88
Price to Book MRQ	$-14.48
Enterprise to Revenue	0.41
Enterprise to EBITDA	1.11

Financial Reports as of Mar. 31, 2025

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2025-03-31
Profit Margin	38.14%
Operating Margin	77.40%
Return on Assets TTM	19.97%
Return on Equity TTM	30.06%

Income Statement

Revenue TTM	$1,254,962,048
Revenue per Share TTM	$7.97
Quarterly Revenue Growth	610.30%
Gross Profit TTM	$732,558,016
EBITDA	$467,502,016
Net Income to Common TTM	$478,696,992
Diluted EPS TTM	$2.75
Quarterly Earnings Growth YoY	567.34%

Balance Sheet

Total Cash MRQ	$731,478,976
Total Cash per Share MRQ	$4.52
Total Debt MRQ	$
Total Debt to Equity MRQ	-3.02
Current Ratio MRQ	2.06
Book Value per Share MRQ	$-0.47

Cash Flow

Operating Cash Flow TTM	$-189,210,000
Levered Free Cash Flow TTM	$61,875,752

NVAX Stock Info as of Jul. 5, 2025

Stock Statistics

Shares Outstanding	160,421,136
Float Shares	136,652,754
Avg 10 Volume	4,565,690
Avg 30 Volume	None
Shares Short	44,482,397
Short Ratio	4.04
Short % of Shares	27.56%
% Held by Insiders	8.78%
% Held by Institutions	57.19%

Stock Price Summary

Beta	2.77
Fifty Two Week Low	$5.01
Fifty Two Week High	$17.81
Fifty Two Week Change	-77.35%
Day 50 MA	$6.77
Day 200 MA	$8.42

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date	2019-05-10
Ex Dividend Date
Last Split Factor
Last Split Date	2019-05-10